AMENDMENTS TO THE SPECIFICATION

Please amend the specification as follows:

Please amend Table 1 spanning pages 7-8, by increasing the line spacing from single-line spacing to 1½-line spacing, as shown below:

Table 1

Amino Acid	One-Letter Abbreviation	Three-Letter Abbreviation
Alanine	A	Ala
Arginine	R	Arg
Asparagine	N	Asn
Aspartic Acid	D	Asp
Cysteine	C	Cys
Glutamine	Q	Gln
Glutamic Acid	E	Glu
Glycine	G	Gly
Histidine	H	His
Isoleucine	I	Ile
Leucine	L	Leu
Lysine	K	Lys
Methionine	M	Met
Phenylalanine	F	Phe
Proline	P	Pro
Serine	S	Ser
Threonine	T	Thr
Tryptophan	W	Trp
Tyrosine	Y	Tyr
Valine	V	Val

Please amend Table 2, beginning on page 18, line 13, by increasing the line spacing from single-line spacing to 1½-line spacing, as shown below (no additions or deletions to the amino acid sequences are to be made to Table 2):

Table 2

Amino Acid Sequences of Edg Receptors

Human Edg 1 (SEQ ID NO: 1) Genbank Accession No. AF233365

MGPTSVPLVKAHRSSVSDYVNYDIIVRHYNYTGKLNISAD
KENSIKLTSVVFILICCFIILENIFVLLTI*WKTKKFHRPM*
YYFIGNLALSDLLAGVAYTANLLLSGATTYKLTPAQWFLR
EGSMFVALSASVFSLLAIAI*ERYITMLKMKLHNGSNNFR*L
FLLISACWVISLILGGLPIMGWNCISALSSCSTVLPLYHK
HYILFCTTVFTLLLLSIVILYCRIYSLV*RTRSRRLTFRKN*
*ISKASRSSEKSLALLK*TVIIVLSVFIACWAPLFILLLLDV
GCKVKTCDILFRAEYFLVLAVLNSGTNPIIYTL*TNKEMRR*
AFIRIMSCCKCPSGDSAGKFKRPIIAGMEFSRSKSDNSSH
PQKDEGDNPETIMSSGNVNSSS

Human Edg 2 (SEQ ID NO: 30) Genbank Accession No. U78192

MAAISTSIPVISQPQFTAMNEPQCFYNESIAFFYNRSGKH
LATEWNTVSKLVMGLGITVCIFIMLANLLVMVAI*YVNRRF*
*HF*PIYYLMANLAAADFFAGLAYFYLMFNTGPNTRRLTVST
WLLRQGLIDTSLTASVANLLAIAI*ERHITVFRMQLHTRMS*
*NRR*VVVVIVVIWTMAIVMGAIPSVGWNCICDIENCSNMAP
LYSDSYLVFWAIFNLVTFVVMVVLYAHIFGYV*RQRTMRMS*
*RHSSGPRRNRDTMMSLLK*TVVIVLGAFIICWTPGLVLLLL
DVCCPQCDVLAYEKFFLLLAEFNSAMNPIIYSY*RDKEMSA*
TFRQILCCQRSENPTGPTEGSDRSASSLNHTILAGVHSND
HSVV

Human Edg 3 (SEQ ID NO: 2) Genbank

MATALPPRLQPVRGNETLREHYQYVGKLAGRLKEASEGST
LTTVLFLVICSFIVLENLMVLIAI*WKNNKFHN*RMYFFIGN
LALCDLLAGIAYKVNILMSGKKTFSLSPTVWFLREGSMFV
ALGASTCSLLAIAI*ERHLTMIKMRPYDANKRHR*VFLLIGM

Accession No.	CWLIAFTLGALPILGWNCLHNLPDCSTILPLYSKKYIAFC
X83864	ISIFTAILVTIVILYARIYFLV*KSSSRKVANHNNSERSMA*
	*LLR*TVVIVVSVFIACWSPLFILFLIDVACRVQACPILFKA
	QWFIVLAVLNSAMNPVIYTL*ASKEMRRAFFRLVCNCLVRG*
	RGARASPIQPALDPSRSKSSSSNNSSHSPKVKEDLPHTDP
	SSCIMDKNAALQNGIFCN

Human Edg 4	MVIMGQCYYNETIGFFYNNSGKELSSHWRPKDVVVVALGL
(SEQ 1D NO: 31)	TVSVLVLLTNLLVIAAI*ASNRRFHQ*PIYYLLGNLAAADLF
	AGVAYLFLMFHTGPRTARLSLEGWFLRQGLLDTSLTASVA
Genbank	TLLAIAV*ERHRSVMAVQLHSRLPRG*RVVMLIVGVWVAALG
Accession No.	LGLLPAHSWHCLCALDRCSRMAPLLSRSYLAVWALSSLLV
AF233092	FLLMVAVYTRI*FFYVRRRVQRMAEHVSCHPRYRETTLSLV*
	*K*TVVIILGAFVVCWTPGQVVLLLDGLGCESCNVLAVEKYF
	LLLAEANSLVNAAVYSC*RDAEMRRTFRRLLCCACLRQSTR*
	ESVHYTSSAQGGASTRIMLPENGHPLMDSTL

Human Edg 4 mt	MVIMGQCYYNETIGFFYNNSGKELSSHWRPKDVVVVALGL
(SEQ ID NO:32)	TVSVLVLLTNLLVIAAI*ASNRRFHQ*PIYYLLGNLAAADLF
	AGVAYLFLMFHTGPRTARLSLEGWFLRQGLLDTSLTASVA
Genbank	TLLAIAV*ERHRSVMAVQLHSRLPRG*RVVMLIVGVWVAALG
Accession No.	LGLLPAHSWHCLCALDRCSRMAPLLSRSYLAVWALSSLLV
AF011466	FLLMVAVYTRI*FFYVRRRVQRMAEHVSCHPRYRETTLSLV*

KTVVIILGAFVVCWTPGQVVLLLDGLGCESCNVLAVEKYF
LLLAEANSLVNAAVYSCRDAEMRRTFRRLLCCACLRQSTR
ESVHYTSSAQGGASTRIMLPENGHPLMTPPFSYLELQRYA
ASNKSTAPDDLWVLLAQPNQQD

Human Edg 5
(SEQ ID NO: 33)
Genbank
Accession No.
AF034780

MGSLYSEYLNPNKVQEHYNYTKETLETQETTSRQVASAFI
VILCCAIVVENLLVLIAV*ARNSKFHS*AMYLFLGNLAASDL
LAGVAFVANTLLSGSVTLRLTPVQWFAREGSASITLSASV
FSLLAIAI*ERHVAIAKVKLYGSDKSCR*MLLLIGASWLISL
VLGGLPILGWNCLGHLEACSTVLPLYAKHYVLCVVTIFSI
ILLAIVALYVRIYCVV*RSSHADMAAPQTLALLK*TVTIVLG
VFIVCWLPAFSILLLDYACPVHSCPILYKAHYFFAVSTLN
SLLNPV*IYTWRSRDLRREVLRPLQCWRPGVGVQGRRRVGT*
PGHHLLPLRSSSSLERGMHMPTSPTFLEGNTVV

Human Edg 6
(SEQ ID NO: 34)
Genbank
Accession No.
AJ000479

MNATGTPVAPESCQQLAAGGHSRLIVLHYNHSGRLAGRGG
PEDGGLGALRGLSVAASCLVVLENLLVLAAI*TSHMRSRR*W
VYYCLVNITLSDLLTGAAYLANVLL*SGARTFRLAPA*QWFL
REGLLFTALAASTFSLLFTAG*ERFATMVRPVAESGATKTS*
*R*VYGFIGLCWLLAALLGMLPLLGWNCLCAFDRCSSLLPLY
SKRYILFCLVIFAGVLATIMGLYGAIFRLV*QASGQKAPRP*
*AARRKARRLLK*TVLMILLAFLVCWGPLFGLLLADVFGSNL
WAQEYLRGMDWILALAVLNSAVNPIIYSF*RSREVCRAVLS*
FLCCGCLRLGMRGPGDCLARAVEAHSGASTTDSSLRPRDS
FRGSRSLSFRMREPLSSISSVRSI

Human Edg 7
SEQ ID NO: 35)
Genbank
Accession No.
AF127138

MNECHYDKHMDFFYNRSNTDTVDDWTGTKLVIVLCVGTFF
CLFIFFSNSLVIAAV*IKNRKFHF*PFYYLLANLAAADFFAG
IAYVFLMFNTGPVSKTLTVNRWFLRQGLLDSSLTASLTNL
LVIAV*ERHMSIMRMRVHSNLTKKR*VTLLILLVWAIAIFMG
AVPTLGWNCLCNISACSSLAPIYSRSYLVFWTVSNLMAFL
IMVVVYLRIYVYV*KRKTNVLSPHTSGSISRRRTPMKLMK*T
VMTVLGAFVVCWTPGLVVLLLDGLNCRQCGVQHVKRWFLL
LALLNSVVNPIIYSY*KDEDMYGTMKKMICCFSQENPERRP*
SRIPSTVLSRSDTGSQYIEDSISQGAVCNKSTS

Human Edg 8
(SEQ ID NO: 36)
Genbank
Accession No.
AF317676

MESGLLRPAPVSEVIVLHYNYTGKLRGARYQPGAGLRADA
VVCLAVCAFIVLENLAVLLVL*GRHPRFHA*PMFLLLGSLTL
SDLLAGAAYAANILLSGPLTLKLSPALWFAREGGVFVALT
ASVLSLLAIAL*ERSLTMARRGPAPVSSRGR*TLAMAAAAWG
VSLLLGLLPALGWNCLGRLDACSTVLPLYAKAYVLFCVLA
FVGILAAICALYARI*YCQVRANARRLPARPGTAGTTSTRA*
*RRKPRSLALLR*TLSVVLLAFVACWGPLFLLLLLDVACPAR
TCPVLLQADPFLGLAMANSLLNPIIYTL*TNRDLRHALLRL*
VCCGRHSCGRDPSGSQQSASAAEASGGLRRCLPPGLDGSF
SGSERSSPQRDGLDTSGSTGSPGAPTAARTLVSEPAAD

Please amend Table 3, beginning on page 21, line 1, by increasing the line spacing from single-line spacing to 1½-line spacing, as shown below (no additions or deletions to the amino acid sequences are to be made to Table 3):

Table 3

Amino Acid Sequences of Chimeric Edg Receptors

Edg1/3(ct)	MGPTSVPLVKAHRSSVSDYVNYDIIVRHYNYTGKLNISAD
(SEQ ID NO: 3)	KENSIKLTSVVFILICCFIILENIFVLLTI*WKTKKFHR*PM
	YYFIGNLALSDLLAGVAYTANLLLSGATTYKLTPAQWFLR
	EGSMFVALSASVFSLLAIA*IERYITMLKMKLHNGSNNF*RL
	FLLISACWVISLILGGLPIMGWNCISALSSCSTVLPLYHK
	HYILFCTTVFTLLLLSIVILYCRIYSLVR*TRSRRLTFRKN*
	*ISKASRSSEKSLALLKTV*IIVLSVFIACWAPLFILLLLDV
	GCKVKTCDILFRAEYFLVLAVLNSGTNPIIYTLTSKEMRR
	AFFRLVCNCLVRGRGARASPIQPALDPSRSKSSSSNNSSH
	SPKVKEDLPHTDPSSCIMDKNAALQNGIFCN

Edgl/3(i3ct)
(SEQ ID NO: 4)

MGPTSVPLVKAHRSSVSDYVNYDIIVRHYNYTGKLNISAD
KENSIKLTSVVFILICCFIILENIFVLLTI*WKTKKFHR*PM
YYFIGNLALSDLLAGVAYTANLLLSGATTYKLTPAQWFLR
EGSMFVALSASVFSLLA*IAIERYITMLKMKLHNGSNNF*RL
FLLISACWVISLILGGLPIMGWNCISALSSCSTVLPLYHK
HYILFCTTVFTLLLLSIVILYCRIYSLVR**SSSRKVANHNN**
SERSMALLRTVIIVLSVFIACWAPLFILLLLDVGCKVKTC
DILFRAEYFLVLAVLNSGTNPIIYTLT**SKEMRRAFFRLVC**
NCLVRGRGARASPIQPALDPSRSKSSSSNNSSHSPKVKED
LPHTDPSSCIMDKNAALQNGIFCN

Edgl/3(i2i3ct)
(SEQ ID NO:5)

MGPTSVPLVKAHRSSVSDYVNYDIIVRHYNYTGKLNISAD
KENSIKLTSVVFILICCFIILENIFVLLTI*WKTKKFHRP*M
YYFIGNLALSDLLAGVAYTANLLLSGATTYKLTPAQWFLR
EGSMFVALSASVFSLLAIAI**ERHLTMIKMRPYDANKRHR**L
FLLISACWVISLILGGLPIMGWNCISALSSCSTVLPLYHK
HYILFCTTVFTLLLLSIVILYCRIYSLVR**SSSRKVANHNN**
SERSMALLRTVIIVLSVFIACWAPLFILLLLDVGCKVKTC
DILFRAEYFLVLAVLNSGTNPIIYTLT**SKEMRRAFFRLVC**
NCLVRGRGARASPIQPALDPSRSKSSSSNNSSHSPKVKED
LPHTDPSSCIMDKNAALQNGIFCN

Edg 5/3(i3ct)
(SEQ ID NO:37)

MGSLYSEYLNPNKVQEHYNYTKETLETQETTSRQVASAFI
VILCCAIVVENLLVLIAV*ARNSKFHS*AMYLFLGNLAASDL
LAGVAFVANTLLSGSVTLRLTPVQWFAREGSASITLSASV

FSLLAIAI*ERHVAIAKVKLYGSDKSCR*MLLLIGASWLISL
VLGGLPILGWNCLGHLEACSTVLPLYAKHYVLCVVTIFSI
ILLAIVALYVRIYCVV**KSSSRKVANHNNSERSMALLR**TVT
IVLGVFIVCWLPAFSILLLDYACPVHSCPILYKAHYFFAV
STLNSLLNPVIYTW**ASKEMRRAFFRLVCNCLVRGRGARAS**
PIQPALEPSRSKSSSSNNSSHSPKVKEDLPHTDPSSCIMD
KNAALQNGIFCN

Edg8/4(ct) (SEQ ID NO: 38)

MESGLLRPAPVSEVIVLHYNYTGKLRGARYQPGAGLRADA
VVCLAVCAFIVLENLAVLLVL*GRHPRFH*APMFLLLGSLTL
SDLLAGAAYAANILLSGPLTLKLSPALWFAREGGVFVALT
ASVLSLLAIAL*ERSLTMARRGPAPVSSRGR*TLAMAAAAWG
VSLLLGLLPALGWNCLGRLDACSTVLPLYAKAYVLFCVLA
FVGILAAICAL*YARIYCQVRANARRLPARPGTAGTTSTRA*
*RRKPRSLA*LLRTLSVVLLAFVACWGPLFLLLLLDVACPAR
TCPVLLQADPFLGLAMANSLLNPIIYTL**RDAEMRRTFRRL**
LCCACLRQSTRESVHYTSSAQGGASTRIMLPENGHPLMTP
PFSYLELQRYAASNKSTAPDDLWVLLAQPNQQD

Please amend Table 4, beginning on page 35, line 13, by increasing the line spacing from single-line spacing to 1½-line spacing, as shown below (no additions or deletions to the amino acid sequences are to be made to Table 4):

Table 4

PCR Primers for Generating Chimeric Edg 1 Receptors

Primer	Direction	Position	Sequence 5'-3'
Edg-1 (SEQ ID NO: 6)		1	CCC/GCG/GTT/AAC/ATG/GGG/CCC/ACC/AGC/GTC
Edg-3 (SEQ ID NO: 7)	rev	1137	CGC/GGA/TCC/TCA/GTT/GCA/GAA/GAT/CCC
E1/3 CTD (SEQ ID NO: 8)		942	CAT/TTA/CAC/TCT/GAC/CAG/CAA/GGA/GAT/GCG/GCG/G
E1/3 CTD (SEQ ID NO: 9)	rev	942	CCG/CAT/CTC/CTT/GCT/GGT/CAG/AGT/GTA/AAT/GAT/G
E1/3 i2 (SEQ ID NO: 10)		402	GTC/TCC/TCG/CCA/TCG/CCA/TCG/AGC/GGC/ACT/TGA/C
E1/3 i2 (SEQ ID NO:11)	rev	402	GTC/AAG/TGC/CGC/TCG/ATG/GCG/ATG/GCG/AGG/AGA
E1/3 i2 (SEQ ID NO:12)		441	CGC/CAA/CAA/GAG/GCA/CCG/CCT/CTT/CCT/GCT/AAT/C

E1/3 i2 (SEQ ID NO:13)	rev	441	GAT/TAG/CAG/GAA/GAG/GCG/GTG/CCT/ CTT/GTT/GGC/G
E1/3 i3 (SEQ ID NO:14)		684	CTA/CTC/CTT/GGT/CAG/GTC/CAG/CAG/ CCG/TAA/GGT/G
E1/3 i3 (SEQ ID NO:15)	rev	684	CAC/CTT/ACG/GCT/GCT/GGA/CCT/GAC/ CAA/GGA/GTA/G
E1/3 i3 (SEQ ID NO:16)		723	CAC/TGC/TGC/GGA/CCG/TGA/TTA/TCG/ TCC/TGA/GCG/TC
E1/3 i3 (SEQ ID NO:17)	rev	723	GAC/GCT/CAG/GAC/GAT/AAT/CAC/GGT/ CCG/CAG/CAG/TG

Please amend Table 5, beginning on page 38, line 1, by increasing the line spacing from single-line spacing to 1½-line spacing, as shown below (no additions or deletions to the amino acid sequences are to be made to Table 5):

Table 5

PCR Primers for Generating Chimeric Edg 5 Receptors

Primer	Direction	Position	Sequence 5'-3'
Edg-5 (SEQ ID NO:18)		1	CCC/GCG/GTT/AAC/ATG/GGC/AGC/ TTG/TAC/TCG
Edg-3 (SEQ ID NO:19)	rev	1137	CGC/GGA/TCC/TCA/GTT/GCA/GAA/ GAT/CCC
E5/3 (SEQ ID NO:20)		864	CGT/CAT/CTA/CAC/GTG/GGC/CAG/ CAA/GGA/GAT/GCG/G
E5/3 (SEQ ID NO:21)	rev	864	CCG/CAT/CTC/CTT/GCT/GGC/CCA/ CGT/GTA/GAT/GAC/G
E5/3 i3 (SEQ ID NO:22)		633	CAT/CTA/C TG/CGT/GGT/CAA/GTC/ CAG/CAG/CCG/TAA/G
E5/3 i3 (SEQ ID NO:23)	rev	633	CTT/ACG/GCT/GCT/GGA/CTT/GAC/ CAC/GCA/GTA/GAT/G
E5/3 i3 (SEQ ID NO:24)		723	CAC/TGC/TGC/GGA/CCG/TGA/CCA/ TCG/TGC/TAG/GCG/TC
E1/3 i3 (SEQ ID NO:25)	rev	723	GAC/GCC/TAG/CAC/GAT/GGT/CAC/ GGT/CCG/CAG/CAG/TG

Please amend Table 6, beginning on page 39, line 8, by increasing the line spacing from single-line spacing to 1½-line spacing, as shown below (no additions or deletions to the amino acid sequences are to be made to Table 6):

Table 6

PCR Primers for Generating Chimeric Edg 8 Receptors

Primer	Direction	Position	Sequence 5'-3'
Edg-8 (SEQ ID NO:26)		1	CCC/GCG/GTT/AAC/ATG/GAG/TCG/ GGG/CTG/CTG
Edg-4-mut (SEQ ID NO:27)	rev	1149	CGC/GGA/TCC/TCA/GTC/CTG/TTG/ GTT/GGG
E8/4 (SEQ ID NO:28)		920	CCA/TCA/TCT/ACA/CGC/TCC/GAG/ ATG/CTG/AGA/TGC/G
E8/4 (SEQ ID NO:29)	rev	920	CGC/ATC/TCA/GCA/TCT/CGG/AGC/ GTG/TAG/ATG/ATG/G